Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-221,365
Closed -$1.28M 2143
2024
Q3
$1.28M Sell
221,365
-22,477
-9% -$125K ﹤0.01% 1237
2024
Q2
$1.25M Sell
243,842
-17,782
-7% -$90.6K ﹤0.01% 1181
2024
Q1
$1.24M Sell
261,624
-46,523
-15% -$297K ﹤0.01% 1249
2023
Q4
$2.25M Sell
308,147
-1,768
-0.6% -$11.7K ﹤0.01% 1164
2023
Q3
$2.26M Sell
309,915
-6,694
-2% -$59.5K ﹤0.01% 1147
2023
Q2
$3.35M Buy
316,609
+242,190
+325% +$2.4M ﹤0.01% 1059
2023
Q1
$1.13M Buy
74,419
+10,969
+17% +$190K ﹤0.01% 1245
2022
Q4
$1.22M Sell
63,450
-130,465
-67% -$2.62M ﹤0.01% 1272
2022
Q3
$4.01M Buy
+193,915
New +$4.23M ﹤0.01% 1020

Other funds holding ADTN

Amundi's ADTN Position: Q4 2024 in Review

Amundi sold out of Adtran (ADTN) in Q4 2024, closing a stake of 221,365 shares — an estimated $1.28M sold.

Amundi first reported a position in ADTN in Q3 2022 and held it in 9 quarters. The position peaked at $4.01M in Q3 2022. 159 funds tracked by Wall St. Rank hold ADTN as of Q4 2024.

  • Amundi reported no remaining Adtran position as of Q4 2024 after selling out during the quarter.
  • Amundi sold 221,365 Adtran shares in Q4 2024, an estimated $1.28M.
  • Amundi first reported a position in Adtran in Q3 2022 and held it in 9 quarters.
  • Amundi's Adtran position peaked at $4.01M in Q3 2022.
  • 159 funds tracked by Wall St. Rank held Adtran as of Q4 2024.

Based on Amundi's 13F filing for Q4 2024, filed 7 Feb 2025.